Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
Further Publications Urology
Related content
Benign Prostatic Hyperplasia (BPH)
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
J Urol
Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S
doi: 10.1097/JU.0000000000003999
Uro-Oncology
Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial
J Urol
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN
doi: 10.1097/JU.0000000000004020
Further Publications Urology
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
Eur Urol
Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ
doi: 10.1016/j.eururo.2024.04.025
Further Publications Gynecology
Prospective 1-year assessment of within-woman variability of follicular and luteal phase lengths in healthy women prescreened to have normal menstrual cycle and luteal phase lengths
Hum Reprod
Henry S, Shirin S, Goshtasebi A, Prior JC
doi: 10.1093/humrep/deae215
COMMENTED
Erectile and Sexual Functions and Dysfunctions
Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
J Clin Endocrinol Metab
Wittert GA, Robledo KP, Handelsman DJ, Inder WJ, Stuckey BGA, Yeap BB, Bracken K, Allan CA, Jesudason D, Jenkins A, Januszewski AS, Grossmann M
doi: 10.1210/clinem/dgaf060
Overactive BladderUrinary Incontinence
Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial
J Urol
Enemchukwu EA, Kalota S, Robertson K, Ge S, Lu J, Badger H, Mujais S, Peters KM
doi: 10.1097/JU.0000000000004373
Further Publications Urology
Long-Term Outcomes of Recurrent Bulbar Urethral Stricture Treatment With the Optilume Drug-Coated Balloon: 5-year Results From the ROBUST I Study
J Urol
DeLong J, Virasoro R, Pichardo M, Estrella R, Rodríguez Lay R, Espino G, Elliott S
doi: 10.1097/JU.0000000000004229
Menopause
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies
Adv Ther
Kagan R, Cano A, Nappi RE, English ML, Mancuso S, Wu X, Ottery FD
doi: 10.1007/s12325-024-03073-8
Uro-Oncology
Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial
Eur Urol
Yuen-Chun Teoh J, Cheng CH, Tsang CF, Kai-Man Li J, Kwun-Chung Cheng B, Hoi-Chak Chan W, Kwun-Wai Chan W, Churk-Fai Li T, Chiu Y, Law MC, Lok-Hei Leung C, Sze-Ho Ho B, Yue-Kit Lee C, Cheong-Kin Chan R, Shu-Yin Chan E, Chan MT, Hok-Leung Tsu J, Tam HM, Lam KM, So HS, Cho CL, Ng CM, Chan CK, Liu PL, Wing-Hong Chu R, Tsui-Lin Ng A, Chu SK, Yee CH, Yiu MK, Lo KL, Au WH, Ma WK, Ka-Fung Chiu P, Sze-Wan Kwok H, Yip SY, Leung CH, Ng CF, EB-StaR Study Group
doi: 10.1016/j.eururo.2024.04.015